6. Nuclear Medicine

Learning Objectives

• Explain how radiopharmaceuticals combine a radionuclide with a carrier molecule to enable "physiological" rather than purely anatomical imaging
• Distinguish the physics and clinical roles of SPECT (gamma-emitting tracers, e.g., Tc-99m) versus PET (positron-emitting tracers, e.g., F-18 FDG)
• Match common radiotracers to their classic clinical indications (bone scan, V/Q scan, thyroid scintigraphy, myocardial perfusion imaging, FDG-PET)
• Interpret the basic pattern of a bone scan, thyroid scan, and V/Q scan well enough to recognize a "hot" versus "cold" lesion and its significance
• Differentiate diagnostic nuclear medicine from therapeutic uses (I-131 for thyroid disease, radioembolization, PSMA-targeted radioligand therapy)
• Apply core radiation safety principles specific to nuclear medicine, including patient isolation precautions after therapeutic doses
• Identify common pitfalls in interpreting nuclear medicine studies, such as physiological uptake mimicking pathology

Quick Answer

Nuclear medicine uses radiopharmaceuticals — a radioactive isotope attached to a molecule the body handles in a predictable way — to image or treat disease based on function rather than just anatomy. A gamma camera or PET scanner detects the radiation the tracer emits from inside the body, producing images that show where a tissue is metabolically active, perfused, or diseased before structural changes would be visible on CT or X-ray. Classic examples include the bone scan (detects metastases through increased osteoblastic activity), the V/Q scan (detects pulmonary embolism through mismatched ventilation and perfusion), and FDG-PET (detects cancer through increased glucose metabolism). The same principle — targeted radioactive delivery — is also used therapeutically, as in radioactive iodine (I-131) for thyroid cancer and hyperthyroidism. Because nuclear medicine shows physiology, it often detects disease earlier or answers a different question than CT or MRI can.

What Makes Nuclear Medicine Different

Every other imaging modality you've studied so far — X-ray, CT, ultrasound, MRI — sends energy into the body and measures what comes back. Nuclear medicine flips this: you put a small amount of radioactivity inside the patient, and the camera sits outside, passively detecting the radiation the patient is now emitting. That single inversion is why nuclear medicine can answer questions structural imaging cannot.

A bone metastasis might look completely normal on a plain X-ray for months, but the bone's osteoblasts are already reacting to the tumor by laying down new bone — a functional change with no visible structural correlate yet. A bone scan tracer accumulates wherever osteoblastic activity is high, lighting up the lesion long before it would be visible structurally. This is the core teaching point of the whole field: nuclear medicine images function and physiology; CT, MRI, and X-ray image anatomy and structure. The two are complementary, not competing — which is why so many modern studies (PET-CT, SPECT-CT) fuse both in a single scan.

The Radiopharmaceutical: How It Works

A radiopharmaceutical has two parts, and understanding both is the key to understanding every nuclear medicine study you will ever encounter:

1. The radionuclide — the radioactive atom that emits detectable radiation (gamma rays or positrons)
2. The carrier/ligand — the molecule that determines where in the body the radionuclide goes

Change the carrier and you change the clinical question, even if the radionuclide stays the same. Technetium-99m (Tc-99m) is the workhorse radionuclide of diagnostic nuclear medicine — attach it to methylene diphosphonate (MDP) and you get a bone scan; attach it to sestamibi and you get a myocardial perfusion or parathyroid scan; attach it to pertechnetate and you get a thyroid scan. Same isotope, three completely different exams, because the carrier targets three different physiological processes.

Why Tc-99m dominates diagnostic nuclear medicine:

• Ideal gamma energy (140 keV) — high enough to escape the body, low enough for good camera resolution
• Short physical half-life (6 hours) — enough time to complete the study, but the patient isn't radioactive for long afterward
• Easily and cheaply produced on-site from a molybdenum-99/technetium-99m generator ("moly cow"), so hospitals don't need a cyclotron on-site for most studies

SPECT vs. PET: The Two Detection Physics

Students often conflate SPECT and PET because both produce cross-sectional functional images, but the underlying physics — and therefore the tracers you can use — are fundamentally different.

SPECT (Single Photon Emission Computed Tomography) uses radionuclides that decay by emitting a single gamma photon directly (Tc-99m, I-123, Ga-67, In-111). A rotating gamma camera detects these photons from multiple angles and reconstructs a 3D image, similar in concept to CT reconstruction but using emitted rather than transmitted radiation.

PET (Positron Emission Tomography) uses radionuclides that decay by emitting a positron (a positive electron). The positron travels a short distance, collides with a nearby electron, and annihilates — producing two 511 keV gamma photons that fly off in exactly opposite directions. The PET scanner detects these paired photons in "coincidence," which lets it calculate the line along which the annihilation occurred with much greater precision than SPECT's single-photon geometry allows. This is why PET has better spatial resolution and sensitivity than SPECT.

The most important PET tracer by far is F-18 fluorodeoxyglucose (FDG) — a glucose analog. Cells trap FDG in proportion to their glucose metabolism, and because cancer cells are typically hypermetabolic, FDG-PET is the backbone of oncologic staging, restaging, and treatment response assessment.

Diagnostic Applications: The Classic Studies

These are the studies you are expected to recognize by tracer, indication, and pattern.

Bone Scan (Tc-99m MDP)

Detects osteoblastic activity. "Hot spots" (increased uptake) occur wherever bone is actively remodeling — metastases (especially from prostate and breast cancer, which are typically osteoblastic), fractures, infection (osteomyelitis), and Paget disease. A classic exam pattern is multiple, randomly distributed hot spots in the axial skeleton and long bones in a patient with known prostate cancer — the "superscan" pattern of diffuse metastatic disease can even make the scan look deceptively "too clean" because renal excretion of tracer is suppressed by the sheer skeletal uptake.

Ventilation/Perfusion (V/Q) Scan

Uses an inhaled radioactive gas or aerosol (ventilation, e.g., Xenon-133 or Tc-99m DTPA aerosol) and an IV-injected radiolabeled albumin (perfusion, Tc-99m MAA) to compare airflow and blood flow. A pulmonary embolism blocks blood flow to a segment that is still being ventilated normally — a "V/Q mismatch." A matched defect (both ventilation and perfusion reduced in the same area) suggests parenchymal lung disease rather than PE. V/Q scanning remains the test of choice in patients who cannot receive iodinated contrast for CT pulmonary angiography (e.g., renal failure, contrast allergy) and in pregnancy, where it delivers less radiation to breast tissue than CTPA.

Thyroid Scintigraphy (Tc-99m Pertechnetate or I-123)

Distinguishes causes of hyperthyroidism by uptake pattern: diffuse increased uptake suggests Graves disease; a single focal area of intense uptake with suppression of the rest of the gland is a toxic (autonomously functioning) adenoma; patchy, irregular uptake suggests toxic multinodular goiter. A "cold" nodule (focal decreased uptake) does not concentrate the tracer and carries a higher relative risk of malignancy than a "hot" nodule, which is almost always benign because thyroid cancer cells rarely retain the ability to trap iodine/pertechnetate as efficiently as normal thyroid tissue.

Myocardial Perfusion Imaging (Tc-99m Sestamibi or Tetrofosmin)

Performed at rest and after pharmacologic or exercise stress. A perfusion defect present on stress images but not on rest images indicates reversible ischemia (viable myocardium supplied by a stenotic vessel). A defect present on both stress and rest images indicates a fixed defect — infarcted, non-viable scar tissue. This distinction directly changes management: reversible ischemia supports revascularization, while a fixed defect in dead myocardium generally does not benefit from stenting or bypass.

FDG-PET (Oncologic Imaging)

Used for staging, restaging, and monitoring treatment response in many cancers (lymphoma, lung cancer, head and neck cancer, melanoma). Uptake is quantified using the standardized uptake value (SUV); higher SUV generally correlates with more aggressive or higher-grade disease, though inflammation and infection also cause FDG uptake and are an important source of false positives.

Therapeutic Nuclear Medicine

Not every use of radioactivity is diagnostic — the same "targeted delivery" principle used for imaging can deliver a therapeutic dose directly to diseased tissue while sparing much of the rest of the body.

• Radioactive iodine (I-131): The thyroid gland avidly concentrates iodine regardless of whether it comes as a tracer dose or a therapeutic one. A therapeutic dose of I-131 is used to ablate an overactive thyroid in Graves disease or toxic nodular goiter, and to ablate residual thyroid tissue or metastases after thyroidectomy for differentiated thyroid cancer.
• Radioembolization (Y-90 microspheres): Yttrium-90-loaded microspheres are injected directly into the hepatic artery to deliver localized radiation to liver tumors (primary hepatocellular carcinoma or metastases) while sparing normal hepatic parenchyma, which is predominantly perfused by the portal vein.
• PSMA-targeted radioligand therapy (Lu-177 PSMA): A newer approach in metastatic castration-resistant prostate cancer — a ligand targeting prostate-specific membrane antigen delivers a beta-emitting radionuclide directly to tumor cells that overexpress PSMA.
• Radium-223: A calcium-mimetic alpha emitter that concentrates in areas of increased bone turnover (i.e., bone metastases from prostate cancer), delivering highly localized radiation with a very short tissue range, which limits damage to adjacent normal marrow.

Radiation Safety in Nuclear Medicine

Nuclear medicine has a unique safety profile because, unlike X-ray or CT, the patient themselves becomes a radiation source after receiving the dose.

• ALARA still applies, but the practical concerns shift: minimizing time near the patient, maximizing distance, and using shielding when preparing and administering doses.
• Therapeutic doses (especially I-131) require patient isolation precautions — inpatients receiving high-dose I-131 may need to be hospitalized in a shielded room until their radioactivity decays below a regulatory threshold, and outpatients are given specific instructions (e.g., avoiding close/prolonged contact with children and pregnant partners, using separate toilets/flushing twice) for a defined period afterward.
• Pregnancy and breastfeeding are key screening questions before any nuclear medicine study — some radiopharmaceuticals cross into breast milk, requiring a "pump and discard" interval after certain scans (particularly clinically significant after I-131 and less so after most Tc-99m studies).
• Radioactive waste decays according to each isotope's physical half-life and is stored ("decay in storage") until it reaches background levels before disposal — unlike chemical or infectious waste, it isn't neutralized, only allowed to decay.

Common Mistakes

Misconception: A "cold" thyroid nodule on scintigraphy means it is benign, so no further workup is needed.

Why it's wrong: Students often assume "cold equals safe" by analogy with other imaging patterns, but it is the opposite relationship in thyroid scintigraphy. A cold nodule fails to take up tracer because it has lost the normal thyroid cell function of iodine trapping — a pattern seen in cysts and benign adenomas, but also in a meaningful proportion of thyroid cancers.

Correct understanding: Cold nodules require further evaluation, typically ultrasound and fine-needle aspiration biopsy, because malignancy cannot be excluded on scan pattern alone. Hot nodules, in contrast, are almost always benign autonomously functioning adenomas and rarely require biopsy.

---

Misconception: PET and SPECT are basically the same technology with different names.

Why it's wrong: They rely on entirely different decay physics. SPECT detects single gamma photons emitted directly by isotopes like Tc-99m, using a rotating camera and lead collimators to determine photon direction. PET detects pairs of 511 keV photons produced by positron-electron annihilation, using coincidence detection rather than physical collimation.

Correct understanding: This physics difference is why PET has superior spatial resolution and sensitivity, and why PET tracers require a cyclotron-produced positron emitter (F-18, Ga-68) rather than a generator-produced isotope like Tc-99m. The clinical consequence is that PET is preferred for oncologic staging, while SPECT remains the workhorse for organ-specific functional studies like bone and myocardial perfusion scans.

---

Misconception: Any area of increased FDG uptake on a PET scan represents cancer.

Why it's wrong: FDG is a glucose analog, not a cancer-specific tracer. Any cell using glucose at a high rate will take it up — this includes active inflammation, infection, healing surgical or radiation sites, brown fat, and normal high-metabolism tissue like the brain and myocardium.

Correct understanding: FDG-PET findings must always be interpreted alongside clinical history, the SUV, and correlative CT/MRI anatomy. A "positive" PET finding in the wrong clinical context (e.g., recent infection or surgery) is a well-recognized cause of false-positive oncologic staging.

Comparison and Connections

Study	Radiotracer	Detects	Classic Positive Finding
Bone scan	Tc-99m MDP	Osteoblastic activity	Focal or diffuse "hot spots" — metastases, fracture, infection
V/Q scan	Xe-133 (ventilation) / Tc-99m MAA (perfusion)	Airflow vs. blood flow mismatch	Segmental perfusion defect with normal ventilation = PE
Thyroid scintigraphy	Tc-99m pertechnetate or I-123	Iodine-trapping function	Diffuse uptake (Graves), focal hot nodule (toxic adenoma), cold nodule (?malignancy)
Myocardial perfusion imaging	Tc-99m sestamibi/tetrofosmin	Regional blood flow at rest and stress	Reversible defect = ischemia; fixed defect = infarct/scar
FDG-PET	F-18 FDG	Glucose metabolism	Focal hypermetabolism = malignancy, infection, or inflammation
PSMA-PET	Ga-68 or F-18 PSMA ligand	Prostate-specific membrane antigen expression	Sites of prostate cancer recurrence/metastasis
I-131 therapy	I-131 (therapeutic dose)	N/A — treatment, not imaging	Ablation of thyroid tissue (Graves, cancer remnants)

Practice Questions

Recall

1. What are the two structural components of any radiopharmaceutical, and what role does each play? Answer guidance: The radionuclide (emits detectable radiation — gamma photon for SPECT, positron for PET) and the carrier/ligand molecule (determines biodistribution — where in the body the tracer goes). The carrier is what makes the study specific to an organ or process, even when the same radionuclide, like Tc-99m, is reused across many different exams.

2. Name three clinically distinct studies that all use Tc-99m as the radionuclide, and state what carrier molecule differentiates each. Answer guidance: Bone scan (Tc-99m MDP), myocardial perfusion imaging (Tc-99m sestamibi or tetrofosmin), and thyroid scan (Tc-99m pertechnetate). The carrier molecule, not the isotope, determines what physiological process is being imaged.

Understanding

3. Explain why PET has better spatial resolution than SPECT in terms of the underlying detection physics. Answer guidance: PET detects two 511 keV photons emitted in opposite directions from positron-electron annihilation, using electronic coincidence detection to define the line of response with high precision. SPECT relies on physical lead collimators to determine the direction of a single gamma photon, which is a much less precise localization method and reduces both resolution and sensitivity.

4. Why does a bone scan often detect a metastatic lesion before it is visible on a plain X-ray? Answer guidance: A bone scan images osteoblastic activity (a functional/physiological response), which increases as soon as the bone reacts to a metastatic deposit. Plain X-ray requires a structural change — roughly 30-50% of bone mineral must be lost before a lytic lesion becomes visible — so the functional change on nuclear imaging precedes the anatomical change detectable on X-ray.

Application

5. A 68-year-old man with known prostate cancer undergoes a bone scan showing innumerable, symmetric foci of increased uptake throughout the axial skeleton, with faint or absent visualization of the kidneys. What does this pattern suggest, and why can it be misleading? Answer guidance: This is a "superscan," indicating diffuse osteoblastic metastatic disease. It can be misleading because the near-absent renal uptake (normally visible as the tracer is excreted) might make an inexperienced reader think the study is "too clean" or technically inadequate, when in fact the near-total skeletal uptake of tracer is what has suppressed the renal excretion pathway — this pattern is a marker of extensive, often lethal, bony metastatic burden.

6. A pregnant patient presents with sudden dyspnea and suspected pulmonary embolism, but has a contrast allergy and reduced renal function. What nuclear medicine study is most appropriate, and why? Answer guidance: A V/Q scan. It avoids iodinated contrast (relevant given the contrast allergy and renal impairment) and, in the specific context of pregnancy, delivers a lower radiation dose to maternal breast tissue than CT pulmonary angiography, making it the preferred option when clinically feasible.

Analysis

7. Compare the clinical utility of a "hot" versus "cold" thyroid nodule, and explain why the risk implications are the opposite of what students commonly expect. Answer guidance: A hot nodule autonomously produces thyroid hormone and takes up tracer avidly, suppressing the rest of the gland; these are almost always benign toxic adenomas. A cold nodule fails to concentrate tracer because it has lost normal iodine-trapping function, which happens in benign cysts/adenomas but also in cancer, so cold nodules require biopsy while hot nodules generally do not. The counterintuitive part is that "hot" (functionally active) is reassuring, while "cold" (functionally silent) is the pattern requiring further workup — opposite to how students often assume "more activity equals more concerning."

8. A patient has an FDG-PET scan for lymphoma staging performed two weeks after major surgery, showing increased uptake at the surgical site. How should this finding be interpreted, and what does it illustrate about the limitations of FDG-PET? Answer guidance: This is very likely a false positive due to post-surgical inflammation and healing, both of which are hypermetabolic processes that avidly take up FDG just like malignant tissue. It illustrates that FDG is not cancer-specific — it is a marker of glucose metabolism generally — so timing relative to recent surgery, infection, or radiation must always be factored into interpretation, and PET is typically deferred for several weeks after surgery for this reason.

FAQ

Why can't every hospital just use PET for everything if it has better resolution than SPECT? Cost and tracer logistics. PET tracers use cyclotron-produced positron emitters (like F-18) with very short half-lives (F-18 is about 110 minutes), which usually requires either an on-site cyclotron or fast regional delivery from a radiopharmacy. SPECT tracers like Tc-99m are produced on-site from a relatively inexpensive generator with a 6-hour half-life, making them far more accessible and affordable for routine, high-volume studies like bone and cardiac scans. PET is reserved for indications, mainly oncologic, where its higher resolution and sensitivity meaningfully change management.

What is the difference between a bone scan and an X-ray for detecting metastases? A bone scan detects the bone's physiological response (osteoblastic activity) to a lesion and can be positive before a structural abnormality is visible on X-ray, making it more sensitive for early detection. However, a bone scan is not specific — fractures, arthritis, and infection also cause increased uptake — so a positive bone scan often needs correlation with plain films, CT, or MRI to confirm the cause of the abnormal focus.

Why do patients need to avoid contact with pregnant women or young children after some nuclear medicine treatments? After a therapeutic dose (most notably I-131 for thyroid disease), the patient's body remains a radiation source until the isotope decays and is excreted. Radiation exposure to a fetus or a child's rapidly dividing tissues carries a disproportionately higher risk than to an adult, so precautions like maintaining distance, limiting time in close contact, and following specific hygiene instructions are given for a defined period based on the administered dose and the isotope's half-life.

Is nuclear medicine radiation dangerous compared to a CT scan? It depends on the specific study, but many diagnostic nuclear medicine exams deliver radiation doses in a similar range to CT, sometimes lower. For example, a standard bone scan delivers roughly 4-6 mSv, comparable to an abdominal CT. What's different is the biologic distribution: dose from nuclear medicine is delivered internally over the tracer's residence time in the body rather than externally in a single pass, and the organs receiving the highest dose depend on where the tracer concentrates and is excreted (often the bladder, since most tracers are renally cleared).

Why does a myocardial perfusion scan need both a stress and a rest image? Comparing the two is what distinguishes viable, ischemic myocardium from dead, infarcted tissue — a distinction that cannot be made from either image alone. A defect that appears only under stress and resolves at rest indicates a flow-limiting coronary stenosis supplying myocardium that is still alive and would benefit from revascularization. A defect present at both rest and stress indicates scar tissue with no blood flow to preserve, which generally would not benefit from a stent or bypass to that territory.

Quick Revision

• Nuclear medicine images function/physiology; CT, MRI, and X-ray image anatomy/structure — the two approaches are complementary
• A radiopharmaceutical = radionuclide (emits radiation) + carrier molecule (determines biodistribution/target)
• Tc-99m is the SPECT workhorse: 140 keV gamma energy, 6-hour half-life, produced cheaply on-site from a Mo-99/Tc-99m generator
• SPECT detects single gamma photons using rotating cameras and physical collimation; PET detects paired 511 keV annihilation photons via coincidence detection — PET has superior resolution
• Bone scan (Tc-99m MDP): detects osteoblastic activity — hot spots in metastases, fracture, infection, Paget disease; diffuse uptake = "superscan"
• V/Q scan: ventilation-perfusion mismatch = pulmonary embolism; preferred over CTPA in pregnancy and renal impairment/contrast allergy
• Thyroid scan: diffuse uptake = Graves; focal hot nodule = toxic adenoma (benign); cold nodule = needs biopsy (higher malignancy risk)
• Myocardial perfusion imaging: reversible defect (stress only) = ischemia; fixed defect (stress and rest) = infarct/scar
• FDG-PET: images glucose metabolism, backbone of oncologic staging; not cancer-specific — inflammation/infection/surgery cause false positives
• Therapeutic nuclear medicine: I-131 (thyroid ablation), Y-90 radioembolization (liver tumors), Lu-177 PSMA (prostate cancer), Radium-223 (bone metastases)
• Radiation safety is unique here because the patient becomes the radiation source; therapeutic I-131 doses require isolation precautions and specific hygiene instructions
• Always screen for pregnancy/breastfeeding before any nuclear medicine study

Related Topics

Prerequisites: X-ray Techniques, basic atomic/nuclear physics (radioactive decay, half-life), introductory anatomy of thyroid, skeletal, cardiac, and pulmonary systems

Related Topics: CT Scan and MRI (structural correlation and fusion imaging), Interventional Radiology, radiation safety principles, oncology staging systems

Next Topics: PET-CT and Hybrid Imaging, Interventional Radiology, Radiation Oncology Principles